Download MendeleyDiscovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Barlaam, B., Casella, R., Cidado, J., Cook, C., De Savi, C., Dishington, A., Donald, C.S., Drew, L., Ferguson, A.D., Ferguson, D., Glossop, S., Grebe, T., Gu, C., Hande, S., Hawkins, J., Hird, A.W., Holmes, J., Horstick, J., Jiang, Y., Lamb, M.L., McGuire, T.M., Moore, J.E., O'Connell, N., Pike, A., Pike, K.G., Proia, T., Roberts, B., San Martin, M., Sarkar, U., Shao, W., Stead, D., Sumner, N., Thakur, K., Vasbinder, M.M., Varnes, J.G., Wang, J., Wang, L., Wu, D., Wu, L., Yang, B., Yao, T.(2020) J Med Chem 63: 15564-15590
- PubMed: 33306391
- DOI: https://doi.org/10.1021/acs.jmedchem.0c01754
- Primary Citation of Related Structures:
6Z45 - PubMed Abstract:
A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2 ), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24 , a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.
Organizational Affiliation:
Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom.
